Biotech

Corcept Therapeutics Announces $30 Million Synthetic, Capped Royalty Transaction; Terminates Committed Equity Financing Facility

MENLO PARK, CA: ...

Agennix Reports Results of FORTIS-M Phase III Trial With Talactoferrin Alfa in Non-Small Cell Lung Cancer

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX: ...

Cellceutix Reports Its Very Novel Anti-Cancer Agent, Kevetrin, at Dana-Farber for Start of Clinical Trials

BEVERLY, MA: ...

Sunshine Heart Announces Conditional Approval From FDA for Its Next Generation C-Pulse(R) System Driver

EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA: ...

Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement for Nucleic Acid Chemistry

BOTHELL, WA: ...

Medivation Announces Second Quarter 2012 Financial Results Teleconference on August 9, 2012

SAN FRANCISCO, CA: ...

Threshold Pharmaceuticals Reports Second Quarter 2012 Financial and Operational Results

SOUTH SAN FRANCISCO, CA: ...

West Announces Record Second Quarter Results, Raises 2012 EPS Guidance

LIONVILLE, PA: Conference Call Scheduled for 9 a.m. Today ...

Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Target Price to $3.50

SAN FRANCISCO, CA: ...

Cytokinetics, Incorporated Reports Second Quarter 2012 Financial Results

SOUTH SAN FRANCISCO, CA: Company Updates Financial Guidance in Connection With Recent Financing and Announces Plans to Initiate Potential Registration Program for Tirasemtiv (CK-2017357) ...